ArticleEuropean journal of neurology2024
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.Basic & clinical pharmacology & toxicology · 2026Review
- Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS-Park Cohort.Movement disorders clinical practice · 2026Observational
- A transdiagnostic approach to non-motor symptoms in Parkinson's disease: exploring internalizing, bipolar spectrum, and impulsive compulsive behavior profiles via cluster analysis.Frontiers in aging neuroscience · 2026Article
- Uric Acid and Impulse Control Disorders in Parkinson's Disease: A Cross-Sectional Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Validation of the Turkish Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (Quip-Rs).Psychiatry and clinical psychopharmacology · 2025Article
- Behavioral disorders in Parkinson disease: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease.Journal of neurology · 2025Article
- Neural network localization in Parkinson's disease with impulse control disorders.Frontiers in aging neuroscience · 2025Article
- DRD4 gene polymorphism and impulse control disorder induced by dopamine agonists in Parkinson's disease.Annals of clinical and translational neurology · 2024Article
- Impulse Control Disorders in Parkinson's Disease and Atypical Parkinsonian Syndromes-Is There a Difference?Brain sciences · 2024Article
- Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.European journal of neurology · 2024Article
- Evaluating impulse control disorders in people with Parkinson's disease: agreement and added value of patient and caregiver reports.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
background and purposeImpulse control disorders (ICDs) are common among Parkinson's disease patients using dopamine agonists. We wanted to determine whether ICD patients have higher dopamine agonist serum concentrations than those without any sign of ICD.
methodsPatients who used either pramipexole or ropinirole depot once daily were screened for ICDs using the validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Those who scored above the cut-off for one or more of the four defined ICDs (gambling, compulsive sexual behavior, compulsive shopping, and binge-eating) were compared in a case-control study to patients who scored zero points (no evidence of ICD) on the same items. They were examined clinically and evaluated using relevant scales. Three blood samples were taken on the same day: before daily dose, and then 6 and 12 h later.
resultsForty-six patients were included: 19 ICD-positive and 27 controls. Ropinirole serum concentrations 6 h after daily intake (C
conclusionsThe use of pramipexole may in itself confer high ICD risk, whereas ICDs among ropinirole users depend more on serum concentration and drug exposure. The pharmacokinetic properties of ropinirole make it challenging to predict its effects on patients, which supports the need for therapeutic drug monitoring to reduce risk of ICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.